EA201990652A1 - Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения - Google Patents

Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения

Info

Publication number
EA201990652A1
EA201990652A1 EA201990652A EA201990652A EA201990652A1 EA 201990652 A1 EA201990652 A1 EA 201990652A1 EA 201990652 A EA201990652 A EA 201990652A EA 201990652 A EA201990652 A EA 201990652A EA 201990652 A1 EA201990652 A1 EA 201990652A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
active ingredients
composition containing
producing
fluorophenyl
Prior art date
Application number
EA201990652A
Other languages
English (en)
Russian (ru)
Inventor
Алена Прокопова
Ярослава Свободова
Ондрей Даммер
Петр Микес
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201990652A1 publication Critical patent/EA201990652A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201990652A 2016-09-05 2017-08-31 Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения EA201990652A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2016-539A CZ2016539A3 (cs) 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
PCT/CZ2017/050037 WO2018041282A1 (en) 2016-09-05 2017-08-31 A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof

Publications (1)

Publication Number Publication Date
EA201990652A1 true EA201990652A1 (ru) 2019-08-30

Family

ID=59955311

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990652A EA201990652A1 (ru) 2016-09-05 2017-08-31 Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения

Country Status (13)

Country Link
US (1) US11786526B2 (enExample)
EP (1) EP3506888A1 (enExample)
JP (1) JP7094944B2 (enExample)
KR (1) KR102517765B1 (enExample)
CN (1) CN110418637A (enExample)
CZ (1) CZ2016539A3 (enExample)
EA (1) EA201990652A1 (enExample)
IL (1) IL265172B (enExample)
MA (1) MA46100A (enExample)
MX (1) MX389761B (enExample)
TW (1) TWI811195B (enExample)
WO (1) WO2018041282A1 (enExample)
ZA (1) ZA201901342B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
WO2022023206A1 (en) * 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
CN120000605A (zh) * 2025-04-21 2025-05-16 山东齐都药业有限公司 瑞舒伐他汀依折麦布制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60319983T2 (de) * 2003-09-01 2009-07-23 Jpm - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
HUE038048T2 (hu) * 2009-07-28 2018-09-28 Egyt Gyogyszervegyeszeti Gyar Új granulálási eljárás és ezzel elõállított granulátum
TR201009397A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2013066279A1 (en) 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
US9763885B2 (en) * 2012-05-01 2017-09-19 Althera Laboratories Ltd. Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
CN103585157B (zh) * 2013-11-13 2016-02-03 武汉武药科技有限公司 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101977785B1 (ko) * 2014-06-25 2019-05-14 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
FR3030251B1 (fr) * 2014-12-22 2018-11-02 L'oreal Composition comprenant un compose 4-(heterocycloalkyl)-benzene-1,3-diol et un solvant particulier
CN105310993A (zh) 2015-11-17 2016-02-10 深圳信立泰药业股份有限公司 一种含有依折麦布的药物组合物及其制备方法

Also Published As

Publication number Publication date
MA46100A (fr) 2019-07-10
TW201818938A (zh) 2018-06-01
MX2019002516A (es) 2019-06-17
TWI811195B (zh) 2023-08-11
JP2019526591A (ja) 2019-09-19
ZA201901342B (en) 2020-10-28
US20200009136A1 (en) 2020-01-09
CZ2016539A3 (cs) 2018-03-14
IL265172A (en) 2019-05-30
WO2018041282A1 (en) 2018-03-08
IL265172B (en) 2022-09-01
MX389761B (es) 2025-03-20
JP7094944B2 (ja) 2022-07-04
US11786526B2 (en) 2023-10-17
EP3506888A1 (en) 2019-07-10
CN110418637A (zh) 2019-11-05
KR20190045286A (ko) 2019-05-02
KR102517765B1 (ko) 2023-04-03
BR112019004269A2 (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
EA201990652A1 (ru) Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения
EA202190086A1 (ru) Соединения-антагонисты pcsk9
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
RU2011144763A (ru) 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
EA201691302A1 (ru) Новые гетероциклические соединения
NZ627385A (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201692003A1 (ru) Макроциклические производные пиримидина
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20161363A1 (es) Moduladores del receptor acoplado a la proteina g40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
JP2017502063A5 (enExample)
EA201890361A1 (ru) Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
EA201491982A1 (ru) Антибактериальные хинолиновые производные